Table 5.

Multi-adjusted contributions of age to the severity of SAD among IOS-defined SAD subjects (n = 603) from total subjects

Outcomes for SAD markers	Unstandardized β	Standardized β	95% CI	P value
CT
LAA−950, %	0.64	0.07	− 0.07, 1.34	0.078
LAA−856, %	6.12	0.21	4.13, 8.14	< 0.001
RV, L	0.16	0.11	0.05, 0.26	0.003
TLC, L	− 0.17	− 0.11	− 0.28, − 0.07	0.001
IOS
R5, Ka/L/s	0.01	0.04	− 0.01, 0.02	0.382
R20, Ka/L/s	− 0.00	− 0.01	− 0.01, 0.01	0.755
R5–R20, Ka/L/s	0.01	0.07	− 0.00, 0.01	0.116
X5, Ka/L/s	− 0.02	− 0.16	− 0.03, − 0.01	< 0.001
AX, Ka/L	0.18	0.12	0.06,0.30	0.004
Fres, Hz	0.80	0.14	0.32,1.29	0.001
Postbronchodilator
MMEF, %predicted	− 6.17	− 0.22	− 8.20, − 4.13	< 0.001
FEF50, %predicted	− 7.01	− 0.22	− 9.31, − 4.72	< 0.001
FEF75, %predicted	− 4.02	− 0.15	− 6.20, − 1.84	< 0.001

All the models were adjusted for sex, BMI, smoking status, smoking index, educational level, asthma, tuberculosis, chronic bronchitis, annual household income, smokers living at home, parental history of respiratory disease, occupation exposure > 6 months, indoor exposure to biomass for cooking or heating. All the variables of age in these models indicate per 10 years increase. Definitions of abbreviations see Table 1